ArticleBMC geriatrics2026
24-hour urinary creatinine as a predictor of lumbar spine bone mineral density change after one-year of zoledronic acid treatment in older postmenopausal women with osteoporosis: a cohort study.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe prediction of bone mineral density (BMD) response to osteoporosis treatment remains challenging as current prediction models rely on complex clinical data or sequential BMD measurements. This study aims to research the association between baseline 24-hour urinary creatinine excretion (24 h Ucr) and the change of BMD after treatment with zoledronic acid (ZOL) and develop an effective model for BMD improvement prediction in older postmenopausal women with osteoporosis.
methodsA total of 135 postmenopausal women (aged ≥ 60 years) with osteoporosis receiving ZOL treatment were included. Correlation analysis was performed to assess the association of baseline 24 h Ucr with BMD change after one year of ZOL treatment. The prediction model for the changes in BMD was established by multivariable binary logistic regression analysis with backward selection. Bootstrap resampling was used to internally validate the final model.
resultsHigher baseline 24 h Ucr was negatively correlated with lumbar BMD changes (r =－0.230, p = 0.007). After adjusting for confounding factors, baseline 24 h Ucr was found to be an independent predictor of changes in lumbar BMD after ZOL treatment (odds ratio 0.694, 95% confidence interval 0.530–0.908, p = 0.008). The new model logit (P) developed achieved a strong area under the curve (AUC) of 0.831 for discriminating treatment responders. The model was internally validated using the bootstrap re-sampling procedure that calculated small AUC optimisms of 0.018 (95% CI－0.060–0.085).
conclusionOur study identifies baseline 24 h Ucr as a promising, readily available and independent predictor for the response to ZOL therapy. This finding offers a potential tool for personalising geriatric osteoporosis management by identifying patients most likely to achieve significant BMD improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.